Sickle cell disease
DOI:
https://doi.org/10.46765/2675-374X.2025v6n1e294Keywords:
Anemia, Sickle Cell, Hematopoietic Stem Cell Transplantation, Hematology, PediatricsAbstract
Sickle cell disease (SCD) is known as the most common hemoglobin disorder, with severe forms of thalassemia syndromes following closely. Current standard treatments, including transfusions, hydroxyurea, and L-glutamine, still do not significantly improve life expectancy and quality of life for patients. Allogeneic hematopoietic cell transplantation (HCT) remains the only curative option, showing overall survival and event-free survival rates over 90%, especially in patients under 16 years old. However, only 15% of SCD patients have access to an unaffected family donor. To increase donor availability, alternative sources such as matched unrelated donors, unrelated umbilical cord blood, and haploidentical donors have become viable options for patients without a matched related donor. The aim of this article was to update the Brazilian consensus previously published by the Brazilian Society of Cellular Therapy and Bone Marrow Transplantation in 2021, highlighting the latest developments in the treatment and monitoring of patients with SCD undergoing HCT.
References
1. Ware RE, De Montalembert M, Tshilolo L, Abboud MR. Sickle cell disease. The Lancet. 2017;390(10091):311–23. https://doi.org/10.1016/S0140-6736(17)30193-9 DOI: https://doi.org/10.1016/S0140-6736(17)30193-9
2. Kato GJ, Piel FB, Reid CD, Gaston MH, Ohene-Frempong K, Krishnamurti L, Smith WR, Panepinto JA, Weatherall DJ, Costa FF, Vichinsky EP. Sickle cell disease. Nat Rev Dis Primer. 2018;4:18010. https://doi.org/10.1038/nrdp.2018.11 DOI: https://doi.org/10.1038/nrdp.2018.10
3. Cappelli B, Volt F, Tozatto-Maio K, Scigliuolo GM, Ferster A, Dupont S, Simões BP, Al-Seraihy A, Aljurf MD, Almohareb F, Belendez C, Matthes S, Dhedin N, Pondarre C, Dalle JH, Bertrand Y, Vannier JP, Kuentz M, Lutz P, Michel G, Rafii H, Neven B, Zecca M, Bader P, Cavazzana M, Labopin M, Locatelli F, Magnani A, Ruggeri A, Rocha V, Bernaudin F, de La Fuente J, Corbacioglu S, Gluckman E; Eurocord, the Cellular Therapy and Immunobiology Working Party (CTIWP) and the Paediatric Diseases Working Party (PDWP) of the EBMT. Risk factors and outcomes according to age at transplantation with an HLA-identical sibling for sickle cell disease. Haematologica. 2019;104(12):e543–6. https://doi.org/10.3324/haematol.2019.216788 DOI: https://doi.org/10.3324/haematol.2019.216788
4. Simões BP, Pieroni F, Barros GMN, Machado CL, Cançado RD, Salvino MA, Angulo I, Voltarelli JC. Consenso brasileiro em transplante de células-tronco hematopoéticas: comitê de hemoglobinopatias. Rev Bras Hematol Hemoter. 2010;32(Suppl. 1):46–53. https://doi.org/10.1590/S1516-84842010005000020 DOI: https://doi.org/10.1590/S1516-84842010005000020
5. Stenger EO, Shenoy S, Krishnamurti L. How I treat sickle cell disease with hematopoietic cell transplantation. Blood. 2019;134(25):2249–60. https://doi.org/10.1182/blood.2019000821 DOI: https://doi.org/10.1182/blood.2019000821
6. Limerick E, Abraham A. Across the myeloablative spectrum: hematopoietic cell transplant conditioning regimens for pediatric patients with sickle cell disease. J Clin Med. 2022;11(13):3856. https://doi.org/10.3390/jcm11133856 DOI: https://doi.org/10.3390/jcm11133856
7. Bernaudin F, Socie G, Kuentz M, Chevret S, Duval M, Bertrand Y, Vannier JP, Yakouben K, Thuret I, Bordigoni P, Fischer A, Lutz P, Stephan JL, Dhedin N, Plouvier E, Margueritte G, Bories D, Verlhac S, Esperou H, Coic L, Vernant JP, Gluckman E; SFGM-TC. Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood. 2007;110(7):2749–56. https://doi.org/10.1182/blood-2007-03-079665 DOI: https://doi.org/10.1182/blood-2007-03-079665
8. Darrigo Junior LG, Mello Costa TC, Vieira AK, Albino CD, Navarro Barros GM, Garcia JL, Fortunato LR, Santos FLS, Fonseca G, Guerino-Cunha RL, De Santis GC, Simões BP. Hematopoietic stem cell transplantation in children with hemoglobinopathies: Brazilian Society of Bone Marrow Transplantation Consensus. J Bone Marrow Transplant Cell Ther. 2021;2(4):132. https://doi.org/10.46765/2675-374X.2021v2n4p132 DOI: https://doi.org/10.46765/2675-374X.2021v2n4p132
9. McPherson ME, Hutcherson D, Olson E, Haight AE, Horan J, Chiang KY. Safety and efficacy of targeted busulfan therapy in children undergoing myeloablative matched sibling donor BMT for sickle cell disease. Bone Marrow Transplant. 2011;46(1):27–33. https://doi.org/10.1038/bmt.2010.60 DOI: https://doi.org/10.1038/bmt.2010.60
10. Gluckman E, Cappelli B, Scigliuolo GM, Fuente JDL, Corbacioglu S. Alternative donor hematopoietic stem cell transplantation for sickle cell disease in Europe. Hematol Oncol Stem Cell Ther. 2020;13(4):181–8. https://doi.org/10.1016/j.hemonc.2019.12.011 DOI: https://doi.org/10.1016/j.hemonc.2019.12.011
11. Eapen M, Kou J, Andreansky M, Bhatia M, Brochstein J, Chaudhury S, Haight AE, Haines H, Jacobsohn D, Jaroscak J, Kasow KA, Krishnamurti L, Levine JE, Leung K, Margolis D, Yu LC, Horowitz MM, Kamani N, Walters MC, Shenoy S. Long‐term outcomes after unrelated donor transplantation for severe sickle cell disease on the BMT CTN 0601 trial. Am J Hematol. 2024;99(4):785–8. https://doi.org/10.1002/ajh.27251 DOI: https://doi.org/10.1002/ajh.27251
12. Gluckman E, Fuente J, Cappelli B, Scigliuolo GM, Volt F, Tozatto-Maio K, Rocha V, Tommaso M, O’Boyle F, Smiers F, Cunha-Riehm CBD, Calore E, Bonanomi S, Graphakos S, Paisiou A, Albert MH, Ruggeri A, Zecca M, Lankester AC, Corbacioglu S; Paediatric Diseases (PDWP) and Inborn Errors Working Parties (IEWP) of the EBMT. The role of HLA matching in unrelated donor hematopoietic stem cell transplantation for sickle cell disease in Europe. Bone Marrow Transplant. 2020;55(10):1946–54. https://doi.org/10.1038/s41409-020-0847-z DOI: https://doi.org/10.1038/s41409-020-0847-z
13. Rangarajan HG, Abu-Arja R, Pai V, Guilcher GMT, Soni S. Outcomes of unrelated donor stem cell transplantation with post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in patients with severe sickle cell disease. Biol Blood Marrow Transplant. 2018;24(2):413–7. https://doi.org/10.1016/j.bbmt.2017.10.030 DOI: https://doi.org/10.1016/j.bbmt.2017.10.030
14. Ruggeri A, Eapen M, Scaravadou A, Cairo MS, Bhatia M, Kurtzberg J, Wingard JR, Fasth A, Lo Nigro L, Ayas M, Purtill D, Boudjedir K, Chaves W, Walters MC, Wagner J, Gluckman E, Rocha V; Eurocord Registry; Center for International Blood and Marrow Transplant Research; New York Blood Center. Umbilical cord blood transplantation for children with thalassemia and sickle cell disease. Biol Blood Marrow Transplant. 2011;17(9):1375–82. https://doi.org/10.1016/j.bbmt.2011.01.012 DOI: https://doi.org/10.1016/j.bbmt.2011.01.012
15. Kassim AA, de la Fuente J, Nur E, Wilkerson KL, Alahmari AD, Seber A, Bonfim C, Simões BP, Alzahrani M, Eckrich MJ, Horn B, Hanna R, Dhedin N, Rangarajan HG, Gouveia RV, Almohareb F, Aljurf M, Essa M, Alahmari B, Gatwood K, Connelly JA, Dovern E, Rodeghier M, DeBaun MR. An international learning collaborative phase 2 trial for haploidentical bone marrow transplant in sickle cell disease. Blood. 2024;143(25):2654–65. https://doi.org/10.1182/blood.2023023301 DOI: https://doi.org/10.1182/blood.2023023301
16. Bolaños-Meade J, Fuchs EJ, Luznik L, Lanzkron SM, Gamper CJ, Jones RJ, Brodsky RA. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood. 2012;120(22):4285–91. https://doi.org/10.1182/blood2012-07-438408 DOI: https://doi.org/10.1182/blood-2012-07-438408
17. Brazilian Society of Bone Marrow Transplantation and Cellular Therapy. Proceedings of XXVIII Annual Meeting of Brazilian Society of Bone Marrow Transplantation and Cellular Therapy. J Bone Marrow Transplant Cell Ther. 2024;5(Suppl. 1). https://doi.org/10.46765/2675-374X.2024v5nSuppl1 DOI: https://doi.org/10.46765/2675-374X.2024v5n1p233
18. Patel DA, Akinsete AM, Connelly JA, Kassim AA. T-cell deplete versus T-cell replete haploidentical hematopoietic stem cell transplantation for sickle cell disease: where are we? Expert Rev Hematol. 2019; 12(9):733–52. https://doi.org/10.1080/17474086.2019.1642103 DOI: https://doi.org/10.1080/17474086.2019.1642103
19. Ciurea SO, Al Malki MM, Kongtim P, Zou J, Aung FM, Rondon G, Chen J, Taniguchi M, Otoukesh S, Nademanee A, Forman SJ, Champlin R, Gendzekhadze K, Cao K. Treatment of allosensitized patients receiving allogeneic transplantation. Blood Adv. 2021;5(20):4031–43. https://doi.org/10.1182/bloodadvances.2021004862 DOI: https://doi.org/10.1182/bloodadvances.2021004862
20. Bernaudin F, Dalle JH, Bories D, de Latour RP, Robin M, Bertrand Y, Pondarre C, Vannier JP, Neven B, Kuentz M, Maury S, Lutz P, Paillard C, Yakouben K, Thuret I, Galambrun C, Dhedin N, Jubert C, Rohrlich P, Bay JO, Suarez F, Raus N, Vernant JP, Gluckman E, Poirot C, Socié G; Société Française de Greffe de Moelle et de Thérapie Cellulaire. Long-term event-free survival, chimerism, and fertility outcomes in 234 patients with sickle-cell anemia younger than 30 years after myeloablative conditioning and matched sibling transplantation in France. Haematologica. 2020;105(1):91–101. https://doi.org/10.3324/haematol.2018.213207 DOI: https://doi.org/10.3324/haematol.2018.213207
21. Abraham A, Hsieh M, Eapen M, Fitzhugh C, Carreras J, Keesler D, Guilcher G, Kamani N, Walters MC, Boelens JJ, Tisdale J, Shenoy S; National Institutes of Health; Center for International Blood and Marrow Transplant Research. Relationship between mixed donor–recipient chimerism and disease recurrence after hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2017; 23(12):2178–83. https://doi.org/10.1016/j.bbmt.2017.08.038 DOI: https://doi.org/10.1016/j.bbmt.2017.08.038
22. Sharma D, Ogbenna AA, Kassim A, Andrews J. Transfusion support in patients with sickle cell disease. Semin Hematol. 2020;57(2):39–50. https://doi.org/10.1053/j.seminhematol.2020.07.007 DOI: https://doi.org/10.1053/j.seminhematol.2020.07.007
23. Angelucci E. How I manage iron overload in the hematopoietic cell transplantation setting. Blood. 2025;145(4):372–82. https://doi.org/10.1182/blood.2023022500 DOI: https://doi.org/10.1182/blood.2023022500
24. Inam Z, Tisdale JF, Leonard A. Outcomes and long-term effects of hematopoietic stem cell transplant in sickle cell disease. Expert Rev Hematol. 2023;16(11):879–903. https://doi.org/10.1080/17474086.2023.2268271 DOI: https://doi.org/10.1080/17474086.2023.2268271
25. Stenger E, Xiang Y, Wetzel M, Gillespie S, Chellapandian D, Shah R, Arnold SD, Bhatia M, Chaudhury S, Eckrich MJ, Kanter J, Kasow KA, Krajewski J, Nickel RS, Ngwube AI, Olson TS, Rangarajan HG, Wobma H, Guilcher GMT, Horan JT, Krishnamurti L, Shenoy S, Abraham A. Long-term organ function after HCT for SCD: a report from the Sickle Cell Transplant Advocacy and Research Alliance. Transplant Cell Ther. 2023; 29(1):47.e1–47.e10. https://doi.org/10.1016/j.jtct.2022.10.012 DOI: https://doi.org/10.1016/j.jtct.2022.10.012
26. Krishnamurti L. Hematopoietic cell transplantation for sickle cell disease: updates and future directions. Hematology. 2021;2021(1):181–9. https://doi.org/10.1182/hematology.2021000251 DOI: https://doi.org/10.1182/hematology.2021000251
27. Shenoy S, Gaziev J, Angelucci E, King A, Bhatia M, Smith A, Bresters D, Haight AE, Duncan CN, de la Fuente J, Dietz AC, Baker KS, Pulsipher MA, Walters MC. Late effects screening guidelines after hematopoietic cell transplantation (HCT) for hemoglobinopathy: Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT. Biol Blood Marrow Transplant. 2018;24(7):1313–21. https://doi.org/10.1016/j.bbmt.2018.04.002 DOI: https://doi.org/10.1016/j.bbmt.2018.04.002
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Luiz Guilherme Darrigo Junior, Roseane Vasconcelos Gouveia, Cilmara Kuwahara, Alexandre de Albuquerque Antunes, Adriana Martins de Sousa , Ana Karine Vieira, Ainá Henriques Melgaço, Juliana Folloni Fernandes, Adriana Seber

This work is licensed under a Creative Commons Attribution 4.0 International License.